Advertisement

Picture EBD Group BIO-Europe Spring 2020 Paris BEU2020 650x75
Document › Details

CRISPR Therapeutics AG. (4/29/19). "Press Release: CRISPR Therapeutics Provides Business Update and Reports First Quarter 2019 Financial Results". Zug & Cambridge, MA.

Organisations Organisation CRISPR Therapeutics AG (Nasdaq: CRSP)
  Group CRISPR Therapeutics (Group)
  Organisation 2 Vertex Pharmaceuticals Inc. (Nasdaq: VRTX)
  Group Vertex Pharmaceuticals (Group)
Products Product CTX001 (CRISPR Therapeutics/Vertex)
  Product 2 CTX120 allogeneic CAR-T cell therapy
Index term Index term Vertex–CRISPR Therapeutics: CRISPR technology, 201510– collab research $75m upfront + $30m investm + milestones + royalties to treat genetic diseases
Persons Person Kulkarni, Samarth (Sam) (CRISPR Therapeutics 201712– promoted CEO before CBO)
  Person 2 Charpentier, Emmanuelle (Helmholtz 201412 Professor at HZI)
     


   
Record changed: 2019-05-04

Advertisement

Picture Kentro Design Corporate and Web Design Berlin 650x65px

More documents for CRISPR Therapeutics (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture Berlin Partner HealthCapital Bionnale 2019 Germany May 650x80px




» top